Ketamine Therapy Experiential Education Study

This interventional trial (n=500) designated as Ketamine Therapy Experiential Education Study (KTEES1), sponsored by Integrative Psychiatry Institute, investigates the effects of low-dose ketamine, administered intramuscularly to clinicians within a psychedelic-assisted therapy (PAT) training programme.

The primary objective is to assess whether a single ketamine-assisted therapy session enhances competencies necessary for mental healthcare professionals providing PAT.

The study commences in September 2022 and is projected to conclude by September 2024. Participants, aged 18-85 and proficient in English, are those enrolled in the IPI Psychedelic Assisted Therapy Training Program. Those administered ketamine must commit to medication dose and attend all study sessions during the In-Person Experiential Training Weekend, and evaluation instruments. They must refrain from certain medications, alcohol, and psychoactive drugs during the study.

Participants will be divided into two groups: one receiving ketamine administration and the other not, with both groups participating in the PAT training programme. Primary outcomes include self-reported measures of therapeutic efficacy and competency, while secondary outcomes involve personality assessment and perceived mystical experiences.

The study utilises observational methods, allocating participants to groups non-randomly, with no masking involved. The primary completion date is estimated for September 2024.

Topic Healthy Subjects
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Integrative Psychiatry Institute
The Integrative Psychiatry Institute (IPI) provides training and education for healthcare professionals in the field of psychedelic-assisted therapy. With a focus on evidence-based practices, IPI's programs are designed to equip therapists, physicians, nurses, and other mental health professionals with the knowledge and skills they need to safely and effectively integrate psychedelic medicines into their practice.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.